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BACKGROUND
The National Lung Screening Trial (NLST) showed that screening with low-dose 
computed tomography (CT) as compared with chest radiography reduced lung-cancer 
mortality. We examined the cost-effectiveness of screening with low-dose CT in 
the NLST.
METHODS
We estimated mean life-years, quality-adjusted life-years (QALYs), costs per person, 
and incremental cost-effectiveness ratios (ICERs) for three alternative strategies: 
screening with low-dose CT, screening with radiography, and no screening. Esti-
mations of life-years were based on the number of observed deaths that occurred 
during the trial and the projected survival of persons who were alive at the end of 
the trial. Quality adjustments were derived from a subgroup of participants who 
were selected to complete quality-of-life surveys. Costs were based on utilization 
rates and Medicare reimbursements. We also performed analyses of subgroups de-
fined according to age, sex, smoking history, and risk of lung cancer and performed 
sensitivity analyses based on several assumptions.
RESULTS
As compared with no screening, screening with low-dose CT cost an additional 
$1,631 per person (95% confidence interval [CI], 1,557 to 1,709) and provided an ad-
ditional 0.0316 life-years per person (95% CI, 0.0154 to 0.0478) and 0.0201 QALYs 
per person (95% CI, 0.0088 to 0.0314). The corresponding ICERs were $52,000 per 
life-year gained (95% CI, 34,000 to 106,000) and $81,000 per QALY gained (95% CI, 
52,000 to 186,000). However, the ICERs varied widely in subgroup and sensitivity 
analyses.
CONCLUSIONS
We estimated that screening for lung cancer with low-dose CT would cost $81,000 
per QALY gained, but we also determined that modest changes in our assumptions 
would greatly alter this figure. The determination of whether screening outside the 
trial will be cost-effective will depend on how screening is implemented. (Funded 
by the National Cancer Institute; NLST ClinicalTrials.gov number, NCT00047385.)
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Lung cancer is the leading cause of cancer-related deaths in the United States1; however, until recently, no method of screen-
ing had been shown to reduce mortality from 
lung cancer. The National Lung Screening Trial 
(NLST) showed that screening with low-dose he-
lical computed tomography (CT) of the chest in 
patients at high risk for lung cancer was associ-
ated with a 20% reduction in lung-cancer mor-
tality.2 Several major medical societies have since 
recommended screening with low-dose CT for 
patients with a similarly high risk of lung can-
cer.3 The U.S. Preventive Services Task Force has 
released a grade B recommendation for low-dose 
CT screening,4 which means that private insur-
ers must cover the cost of screening.5
One major consideration for policymakers is 
the cost-effectiveness of this screening interven-
tion.6 Before publication of the NLST results, 
several cost-effectiveness analyses reported re-
sults ranging from very favorable7,8 to unfavor-
able.9,10 This variation reflected both the uncer-
tainty regarding the effectiveness of screening 
with low-dose CT for lung cancer and the use of 
different methods of analysis. At the inception 
of the NLST, the investigators planned to use the 
results of the trial to conduct cost-effectiveness 
analyses and planned the data collection accord-
ingly.2,11-13 The primary focus of this report is the 
cost-effectiveness of screening with low-dose CT 
as performed in the NLST. The report includes 
an extensive sensitivity analysis, which is rele-
vant to extrapolation beyond the NLST findings 
(see Section 1 in the Supplementary Appendix, 




The NLST was a joint effort of the American 
College of Radiology Imaging Network (ACRIN) 
and the Lung Screening Study (LSS). From Au-
gust 2002 through April 2004, a total of 53,452 
persons were enrolled and randomly assigned to 
undergo three annual screenings with either low-
dose CT or chest radiography.2 Participants were 
followed through December 31, 2009. Major eli-
gibility criteria included an age between 55 and 
74 years and a smoking history of at least 30 pack-
years. The study protocol was approved by the 
institutional review board at each of 33 screen-
ing centers (23 ACRIN centers and 10 LSS centers), 
and written informed consent was obtained from 
each participant before randomization.
Vital status was based on questionnaires ad-
ministered semiannually (ACRIN) or annually 
(LSS); for participants lost to follow-up, status 
was based on data from the National Death In-
dex. Medical records were obtained from partici-
pants who had received positive screening results, 
a diagnosis of lung cancer, or both, and informa-
tion related to diagnostic procedures and lung-
cancer staging and treatment was abstracted with 
the use of forms that were harmonized across 
ACRIN and LSS. More detailed information re-
lated to diagnostic procedures and lung-cancer 
treatment was collected from ACRIN sites to in-
form the cost-effectiveness analysis 14,15 (see Sec-
tion 6 in the Supplementary Appendix). In addi-
tion, data on health-related quality of life were 
collected from participants at 16 of the ACRIN 
screening centers.
Screening Strategies and Study Design
We compared three strategies: screening with low-
dose CT, screening with radiography, and no 
screening. For the two screening strategies, cost 
and health outcomes were based directly on trial 
data. For the strategy of no screening, we as-
sumed that health outcomes would be the same 
as those in the radiography group and that costs 
would equal those in the radiography group mi-
nus the costs of screening examinations and work-
ups for false positive results. We based these as-
sumptions on the results of the Prostate, Lung, 
Colorectal, and Ovarian (PLCO) Cancer Screen-
ing Trial,16 which showed no significant reduc-
tion in lung-cancer mortality or overdiagnosis in 
the group randomly assigned to screening with 
chest radiography.
The analysis conformed to the reference-case 
recommendations of the U.S. Panel on Cost-Effec-
tiveness in Health and Medicine.12 Assuming that 
screening would affect only the costs and health 
benefits related to lung-cancer screening and 
treatment, we conducted the analysis from a so-
cietal perspective, in which all health effects and 
changes in resource use were included.17 We con-
sidered both a within-trial time horizon (with the 
effects of screening observed through December 
31, 2009) and a lifetime horizon. For each strat-
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egy, we estimated life expectancy and quality-
adjusted life expectancy (QALE) from the time of 
randomization (assumed for the sake of simplic-
ity to be January 1, 2009, for all participants). We 
reported costs and life-years on a present-value 
basis, with an annual discount rate of 3%.
Life Expectancy
We assumed that screening did not affect life 
expectancy in participants who did not receive a 
diagnosis of lung cancer and that it did not incur 
costs beyond those involved in the workup for a 
patient with a positive examination result (with 
the exception of potentially clinically significant 
incidental findings and the occurrence of radia-
tion-induced lung cancer in the low-dose CT group 
after the trial4) (see Table S7-5 in the Supplemen-
tary Appendix). During the trial, there were 116 
more lung cancers diagnosed in the CT group 
than in the radiography group. We also assumed 
that all these additional cases resulted from 
overdiagnosis, so that participants in the radiog-
raphy group without a diagnosis of lung cancer 
at the end of the trial had the same future risk 
of lung cancer as those in the CT group. This 
assumption is justified by the near convergence 
of lung-cancer incidence in the two groups in the 
last 3 years of the trial (Table S2-2 and Fig. S2-1 
in the Supplementary Appendix). Given these as-
sumptions, the life expectancies of participants 
without a diagnosis of lung cancer are equal in 
the two groups (with the exception of the radia-
tion-induced lung cancers occurring only in the 
low-dose CT group). The life expectancy associ-
ated with each screening strategy was equal to a 
weighted average of the life expectancies of par-
ticipants with and those without lung cancer.
We excluded 150 of the 53,452 patients who 
underwent randomization: 100 were lost to fol-
low-up within 1 day after randomization or after 
their first screening examination (46 in the CT 
group and 54 in the radiography group), 48 had 
missing data with respect to lung cancer (i.e., there 
were not enough data to predict survival [33 in 
the CT group and 15 in the radiography group]), 
and 2 were younger than 50 years of age at study 
entry (1 patient in each group). For each of the 
remaining 53,302 participants (26,642 in the CT 
group and 26,660 in radiography group), we es-
timated life-years by adding beyond-trial life-years 
to within-trial life-years. We calculated within-
trial life-years from the date of randomization to 
the date of death if the patient was deceased (as 
was the case with 3964 patients); to December 
31, 2009, if the patient was alive; or to the latest 
date on which the patient was known to be alive 
if data on vital status were missing on December 
31, 2009. For the 49,338 participants not known 
to be deceased on December 31, 2009, we esti-
mated beyond-trial life-years on the basis of their 
age on the date they were last known to be alive, 
sex, smoking status at study entry, and lung-cancer 
stage, if any, using 2009 U.S. Life Tables18 adjusted 
for smoking status and stage-specific annual prob-
abilities of dying from lung cancer (Sections 3 and 
4 in the Supplementary Appendix).
We used the observed NLST stage-specific mor-
tality from lung cancer to estimate life expectancy 
for the first 5 years after diagnosis. For subse-
quent years, for which NLST data were sparse, 
we adjusted the observed NLST mortality spe-
cific to disease stage to account for the decline 
in the hazard of death from lung cancer with 
increased time from the time of diagnosis that 
was observed in the Surveillance, Epidemiology, 
and End Results Program19 and that has been ob-
served with long-term follow-up of patients with 
stage I lung cancer detected on CT screening.20
To adjust life expectancy for quality, we used 
utilities derived from the Short Form Health Sur-
vey SF-36,21 which was administered to 11,696 
participants from 16 of 23 ACRIN screening sites. 
At baseline, the mean utilities (a measure of 
quality of life on a scale of 0 [death] to 1 [perfect 
health]) were 0.76 and 0.74 for men and women, 
respectively, and did not differ by age (Section 5 
in the Supplementary Appendix). We also adjust-
ed for lung-cancer stage and time of diagnosis. 
Because there was no significant difference in 
utilities between those with false positive screen-
ing results and those with true negative screen-
ing results, we did not adjust for screening re-
sults in the base case.14 (The base case reflects 
several assumptions made to reduce the com-
plexity of our analysis and minimize the use of 
variables for which there are no reliable esti-
mates. For example, we assumed that all 116 
additional cases diagnosed in the CT group were 
due to overdiagnosis and that there was no re-
duction in quality of life after a positive screen. 
See the Supplementary Appendix for further de-
tails.)
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Costs
We estimated the expected per-person cost relat-
ed to lung cancer for the same cohort of 53,302 
participants used in the estimation of life expec-
tancy. Total per-person costs were calculated as 
the sum of direct medical costs and indirect 
costs. We based direct medical costs on utiliza-
tion related to the screening examination, diag-
nostic workup for positive screening results and 
signs or symptoms of lung cancer, and lung-
cancer treatment, and we calculated these costs 
for each participant each year after randomiza-
tion, using 2009 Medicare prices.22 The frequen-
cy of screening was based on records indicating 
adherence to screening with CT or radiography. 
In the ACRIN subgroup, medical utilization re-
lated to diagnostic workup and treatment of 
lung cancer was obtained directly by means of 
medical-record abstraction (Section 6 in the Sup-
plementary Appendix). We obtained utilization 
data from 5133 of the 18,840 participants in the 
ACRIN subgroup, including almost all those who 
had a positive screening result, a diagnosis of 
lung cancer, or both, and imputed costs for LSS 
participants and ACRIN participants without cost 
data using variables for which data had been 
collected for all participants. We based indirect 
medical costs on time and travel for the partici-
pant and caregiver, using 2009 U.S. pricing for 
hourly earnings23 and automobile-mileage reim-
bursement.24 In the base case, we assigned an 
effective total cost of $500 for a participant with 
at least one potentially clinically significant inci-
dental finding (Section 6.7 in the Supplementary 
Appendix), and we included medical care (during 
and after the trial) for lung cancers diagnosed 
during the trial and for future hypothetical cases of 
lung cancer induced by radiation from CT screening.
Statistical Analysis
The three screening strategies were organized 
according to their baseline costs (from high to 
low). Incremental costs, life expectancies, QA-
LEs, and incremental cost-effectiveness ratios 
(ICERs) were calculated for each strategy after 
the exclusion of any strategy that cost more but 
provided no benefit as compared with another 
strategy. We estimated the statistical uncertainty 
of our results by calculating equal-tail 95% boot-
strap confidence intervals.25,26
We performed analyses in subgroups defined 
according to age (in 5-year age groups), sex, 
smoking status (current vs. former), and quin-
tiles for the risk of lung cancer that were based 
on a recently validated model.27 To assess the 
internal validity of our analysis, we dropped 
three of our base-case assumptions: the assump-
tion that screening with low-dose CT did not af-
fect mortality from causes other than lung can-
cer, the assumption that all excess cases in the 
low-dose CT group were overdiagnoses (and in-
stead considering the possibility that up to half 
of the excess cases were not overdiagnoses),28,29 
and the assumption that screening with chest 
radiography was ineffective in reducing lung-
cancer mortality as compared with no screening 
(Section 7 in the Supplementary Appendix). In ad-
dition, because of the large disparity across groups 
in the numbers of participants with stage IA 
non–small-cell lung cancer who were alive at the 
end of the trial (324 in the CT group vs. 140 in 
the radiography group) and because of the uncer-
tainty regarding their survival more than 5 years 
after diagnosis, we repeated the analysis on the 
basis of optimistic and pessimistic assumptions 
about their long-term survival (Section 4 in the 
Supplementary Appendix). We also performed sen-
sitivity analyses of the quality of life after receipt 
of a positive screening result and after a diagnosis 
of lung cancer, of radiation-induced lung-cancer 
deaths,4 and of overdiagnosis in the radiography 
group. Such overdiagnosis would have violated our 
base-case assumptions with regard to the group 
that received no screening.
To assess the generalizability of our results, we 
performed sensitivity analyses of surgical mor-
tality and of the costs of the low-dose CT screen-
ing examinations, follow-up CT examinations, 
surgical resection, chemotherapy, radiation ther-
apy, time and travel, management of incidental 
findings, and future medical care.
R esult s
Diagnoses and Deaths
Among the 53,302 participants in our analysis, 
1076 in the CT group and 978 in the radiography 
group received a diagnosis of lung cancer (Table 
S2-1 in the Supplementary Appendix). Among 
those in the CT group who had lung cancer, 469 
died from lung cancer and 49 died from other 
causes; among those in the radiography group 
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who had lung cancer, 552 died from lung cancer 
and 35 died from other causes. These numbers 
represent data from the time of study entry 
through December 31, 2009.
Life Expectancy and QALE
Discounted life expectancy and QALE were higher 
in the CT group than in the radiography group, 
and the between-group differences were greater 
when these variables were projected over a life-
time horizon rather than a within-trial horizon 
because the lifetime horizon accounted for life-
years saved after the trial (Table 1). For the ap-
proximately 4% of patients with a diagnosis of 
lung cancer, the incremental life expectancy was 
1.6 years.
Costs and Incremental Cost-Effectiveness
Discounted per-person costs were much higher 
in the CT group than in the radiography group 
(Table 2), mainly because of the cost of the 
screening examination and the much higher 
Medicare reimbursement for a CT scan of the 
chest (without the administration of contrast 
material) than for a chest radiograph ($285 vs. 
$24).22 Per-person costs for diagnostic workups 
and surgery were also higher in the CT group, 
but the per-person costs of chemotherapy and 
radiation therapy were lower than those in the 
radiography group. Future medical costs, which 
were calculated only in the sensitivity analysis, 
were slightly higher in the CT group because a 
Time Horizon Life Expectancy Quality-Adjusted Life Expectancy
CT Radiography CT Radiography
life-yr QALY
Within trial 5.7846 5.7775 4.3390 4.3351
Participants with lung cancer 4.9013 4.6029 3.5603 3.3596
Participants without lung cancer† 5.8228 5.8228 4.3728 4.3728
Lifetime 14.7386 14.7071 10.9692 10.9491
Participants with lung cancer 8.4792 6.8479 6.0521 4.8981
Participants without lung cancer† 15.0097 15.0103 11.1821 11.1825
*  Life-years were discounted at 3% and are defined as follows: within-trial life-years were calculated from the date of ran-
domization to the date of death if the patient was deceased; to December 31, 2009, if the patient was alive; or to the
latest date on which the patient was known to be alive if data on vital status were missing on December 31, 2009. For
participants not known to be deceased by that date, beyond-trial life-years were estimated on the basis of the partici-
pants’ age on the date they were last known to be alive, sex, smoking status at study entry, and lung-cancer stage, if
any, with the use of 2009 U.S. Life Tables,18adjusted for smoking status and stage-specific annual probabilities of dying
from lung cancer. For further details see Sections 3 and 4 in the Supplementary Appendix. The results for participants
who underwent no screening were assumed to be the same as for those who underwent radiographic screening.
†  For participants without lung cancer, outcomes were assumed to be the same for those who underwent CT screening 
and those receiving radiographic screening except for an adjustment for the occurrence of radiation-induced lung can-
cer after the trial.









Total 3,074 1,911 1,443
Screening 1,130† 336 0
Workup 835 645 512
Treatment 1,106 931 931
Surgery 736 470 470
Chemotherapy 282 351 351
Radiation therapy 88 110 110
Radiation-induced lung cancer 3 0 0
*  Costs include those for time and travel, which were $101 for each screening
visit, each workup visit, and each surgical visit. The cost for time and travel
for each radiation therapy visit was $175 and for each chemotherapy visit,
$381.
†  The cost of CT screening includes that of addressing potentially clinically sig-
nificant incidental findings.
Table 2. Costs per Person.*
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higher proportion of participants were still alive 
at the end of the trial. We assumed that per-
person costs in the group undergoing no screen-
ing were the same as those in the group under-
going radiography minus the costs for screening 
and for the workup of false positive screening 
results.
In our base case, screening with radiography 
was more expensive than no screening but pro-
vided no health benefit (Table 3). As compared 
with no screening, screening with low-dose CT 
cost an additional $1,631 (95% confidence inter-
val [CI], 1,557 to 1,709) per person and provided 
an additional 0.0316 life-years per person (95% CI, 
0.0154 to 0.0478) and 0.0201 QALYs per person 
(95% CI, 0.0088 to 0.0314); the corresponding 
ICERs were $52,000 per life-year gained (95% CI, 
34,000 to 106,000) and $81,000 per QALY gained 
(95% CI, 52,000 to 186,000).
Subgroup and Sensitivity Analyses
The incremental costs were relatively stable among 
subgroups, with a range of $1,453 to $1,905 
(Table 4). However, the range for incremental 
QALYs was much wider (0.0027 to 0.0515), with 
the highest QALY value up to nearly 20 times as 
high as the lowest; consequently, the range for 
ICERs was just as wide ($32,000 to $615,000 per 
QALY gained). The ICER was much lower for 
women than for men ($46,000 vs. $147,000 per 
QALY gained), for current smokers than for for-
mer smokers ($43,000 vs. $615,000 per QALY 
gained), for the three oldest age groups than for 
the youngest age group, and for the two quin-
tiles with the highest risk of lung cancer than 
for the three quintiles with the lowest risk.










 QALE Cost per Life-Yr Cost per QALY
U.S. $ life-yr QALY U.S. $ life-yr QALY U.S. $ (95% CI)






1,911 14.7071 10.9491 469 0 0 NA NA
No screening‡ 1,443 14.7071 10.9491 — — — — —
*  All costs were calculated for the base case, which reflects several assumptions made to reduce the complexity of the analysis and minimize
the use of variables for which there are no reliable estimates. NA denotes not applicable, QALE quality-adjusted life expectancy, and QALY
quality-adjusted life-year.
†  Incremental costs are in reference to the strategy of no screening because the radiography strategy cost more but provided no incremental 
health benefit as compared with no screening.
‡  The cost of the strategy of no screening included the cost of the diagnosis and treatment of lung cancer without low-dose CT or radiograph-
ic screening.










U.S. $ QALY U.S. $
Sex
Male 31,446 1,683 0.0115 147,000
Female 21,856 1,557 0.0340 46,000
Age at entry
55–59 yr 22,773 1,541 0.0101 152,000
60–64 yr 16,333 1,520 0.0320 48,000
65–69 yr 9,504 1,900 0.0351 54,000
70–74 yr 4,685 1,905 0.0163 117,000
Smoking status
Former 27,643 1,661 0.0027 615,000
Current 25,659 1,601 0.0369 43,000
Risk of lung cancer
First quintile 10,660 1,453 0.0086 169,000
Second quintile 10,661 1,454 0.0118 123,000
Third quintile 10,660 1,651 0.0061 269,000
Fourth quintile 10,661 1,672 0.0515 32,000
Fifth quintile 10,660 1,851 0.0354 52,000
Table 4. Incremental Costs According to Subgroups.
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our base-case assumptions (Table 5). The ICER 
fell to $54,000 per QALY gained when the reduc-
tion in mortality from causes other than lung 
cancer was included, to $55,000 per QALY gained 
when only half rather than all the excess lung 
cancers in the CT group were attributed to over-
diagnosis, and to $62,000 per QALY gained when 
the risk of death from lung cancer after screen-
ing with chest radiography as compared with no 
screening was reduced to 0.94. However, the ICER 
approached or exceeded $100,000 per QALY gained 
when future health care costs were included; when 
costs for the screening examination, follow-up, 
or surgery were increased; when the pessimistic 
expectations of survival with stage IA non–small-
cell lung cancer were assumed; and when small 
reductions in quality of life related to positive 
screening results and a diagnosis of stage IA lung 
cancer were included. The ICER rose slightly with 
the inclusion of deaths from radiation-induced 
lung cancer.
Discussion
Our base-case estimates of the ICERs for screen-
ing with low-dose CT versus no screening — 
$81,000 per QALY gained and $52,000 per life-
year gained — fall between the two estimates 
reported since the intervention was proven effec-
tive in the NLST and fall below $100,000 per 
QALY gained, a threshold level that some experts 
consider to be a reasonable value in the United 
States.30 Much of the difference between our esti-
mate of ICER and the substantially higher estimate 
reported by McMahon et al.31 can be explained 
by the difference in the number of follow-up CT 
scans per positive screening examination — ap-
proximately one observed in the NLST,32 as com-
pared with four assumed in the study by McMa-
hon et al. Much of the difference between our 
estimate and the lower estimate reported by Py-
enson et al.33 can be explained by their assump-
tion that the reduction in mortality from lung 
cancer that resulted from screening would be 
higher than the 20% observed in the NLST.
The estimated cost-effectiveness of screening 
with low-dose CT varied widely in the subgroup 
analysis. Screening with low-dose CT was much 
more cost-effective among women than among 
men and among the groups with a higher risk of 
lung cancer than among those with a lower risk, 
findings that are consistent with two recent re-
ports showing the greater effectiveness among 
women34 (probably related to different distribu-
tions of lung cancer according to histologic type) 
and among persons at higher risk35 in the NLST. 
Screening with low-dose CT was also more cost-
effective for current smokers than for former 
smokers and for the older groups than for the 
youngest group, findings that are probably due 
to the higher risk of lung cancer among current 
smokers and older patients. However, the trends 
related to age and risk were not uniform, prob-
ably because the numbers of lung cancers reported 
in the subgroups in our study were smaller than 
the numbers in the total sample.
The ICERs reported in our study were highly 
sensitive to several of our base-case assumptions. 
The ICER fell substantially when we excluded 
our assumptions that CT screening did not af-
fect mortality from causes other than lung can-
cer, that all excess lung cancers in the CT group 
were due to overdiagnosis, and that screening 
with chest radiography was ineffective. The ICER 
rose substantially when we included future health 
care costs of survivors that were unrelated to lung 
cancer, but we did not include these costs in our 
base case because their inclusion is controver-
sial12 and because they have not been included in 
prior cost-effectiveness analyses of lung-cancer 
screening.7-10,31,33,35 The ICER also rose substan-
tially when we increased the costs of the screen-
ing examination, follow-up, and surgery and when 
we reduced the quality of life related to positive 
screening results and to a diagnosis of stage IA 
lung cancer.
We observed no loss of utility in our generic 
instruments after a report of positive results, 
a finding that is consistent with another trial, in 
which false positive screening mammograms were 
reported36; however, distress in response to a posi-
tive result (and relief on learning of true negative 
results) were observed in the NELSON trial (Cur-
rent Controlled Trials number, ISRCTN63545820) 
when these emotions were measured with dis-
ease-specific instruments measuring quality of 
life.37 All participants in the NLST were provided 
with detailed information about the frequency 
and clinical significance of false positive results 
before study entry, and patients with positive 
screening results received additional information, 
which may have reduced their distress.
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Although the NLST results suggest that screen-
ing with low-dose CT costs less than $100,000 per 
QALY gained, screening conducted outside the 
trial may be more costly, depending on the vari-
ables that we considered in our sensitivity analy-
ses and on the way in which screening is imple-
mented. One of the most important factors is 
the cost of the low-dose CT screening examina-
tion. Costs could also increase considerably if 
patient counseling and follow-up are properly 
accounted for. As the true cost of screening ap-
proaches $500, the cost becomes prohibitive. The 
cost could also become prohibitive if the number 
of follow-up CT scans were to increase. However, 
the American College of Radiology has developed 
a reporting system that will raise the positivity 
threshold that was used in the NLST and could 
substantially decrease the number of follow-up 
CTs obtained.38
There are several additional limitations to our 
analysis that deserve consideration. First, we ex-
cluded 150 NLST participants from our analysis, 
48 of whom had lung cancer but for whom we 
did not have adequate information to project their 
survival. Because 47 of these participants were 
known to be alive at the end of the trial and more 
of these participants were in the CT group than 
in the radiography group, their exclusion probably 
led to a small bias against screening with low-
dose CT. Second, we assumed that screening with 
low-dose CT did not affect smoking status after 
the time of entry into the NLST.39 To the extent 
that screening caused current smokers to become 
former smokers, we underestimated the cost-
effectiveness of screening with low-dose CT. Fi-
nally, we did not consider numerous factors that 
relate to the generalizability of our results out-
side the NLST, such as the high quality of care 
provided at NLST screening centers and the strin-
gent selection criteria. However, the Cancer In-
tervention and Surveillance Modeling Network 
(CISNET) recently reported an analysis that in-
cludes eligibility criteria and screening intervals.40
In conclusion, we estimate that screening with 
low-dose CT for lung cancer as performed in the 
NLST costs less than $100,000 per QALY gained. 
The determination of whether screening per-
formed outside the trial will be cost-effective will 
depend on exactly how screening is implemented.
No potential conflict of interest relevant to this article was 
reported.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
Scenario Cost per QALY
U.S. $
Base case* 81,000
Inclusion of non–lung-cancer deaths 54,000





No. of future excess cases (0)‡
29 66,000
58 55,000




Cost of screening with low-dose CT ($285)
100 56,000
500 110,000










Future health care costs (0 after CT; 0 after no screening)
$171,018 after CT screening 120,000
$170,248 after no screening
Reduction in quality of life after positive screen (0)
0.05 116,000
Reduction in quality of life after diagnosis of stage IA lung 
cancer (0.03)
0.07 101,000








*  The base case reflects several assumptions made to reduce the complexity of
the analysis and minimize the use of variables for which there are no reliable
estimates. The base-case value for each variable is given in parentheses.
†  The point estimate is for the subgroup of the Prostate, Lung, Colorectal, and 
Ovarian Cancer-Screening Trial that was eligible for the National Lung 
Screening Trial.16
‡  Future excess cases represent the additional number of lung cancers diag-
nosed after the trial in the radiography group as compared with the CT group.
Table 5. Results of Sensitivity Analyses.
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